Navigation Links
Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A.

FREMONT, Calif., May 18, 2011 /PRNewswire/ -- Biomerix Corporation and Cellon today announced a strategic distribution agreement for the Biomerix 3D Scaffold, a novel three-dimensional tissue scaffold. Under the agreement, Cellon will market and distribute the Biomerix 3D Scaffold to research institutions across Europe.

Comprised of a non-degradable, three-dimensional, open-cell polycarbonate polyurethane, the Biomerix 3D Scaffold is designed to mimic the nature and function of the extracellular matrix (ECM). Its novel macroporous microarchitecture consists of a network of interconnecting cells and pores, creating an environment highly conducive to applications in regenerative medicine, drug discovery, and stem cell research.  The unique chemistry and microarchitecture of the Biomerix 3D Scaffold has been demonstrated to support optimal cell proliferation and superior cell viability in both in-vitro and in-vivo studies involving diverse cell types, including hematopoetic stem cells, mesenchymal stem cells, induced pluripotent stem cells, human adipose stem cells, human osteoblasts, fibroblasts, and fibrochondrocytes.

"Biomerix is delighted to form this new strategic partnership with Cellon, further strengthening each company's European presence in the field of regenerative medicine, tissue engineering, and drug discovery, development and delivery.  The proprietary Biomerix Biomaterial used to manufacture the Biomerix 3D Scaffold has received seven US and international regulatory clearances for different indications in soft tissue repair, orthopedics, and vascular embolization," said Kenneth Hayes, President and Chief Executive Officer of Biomerix Corporation.

About Biomerix Corporation

Biomerix Corporation is recognized as a leader in the development and manufacturing of innovative non-absorbable and bioresorbable three-dimensional, open-cell, resilient elastomeric polyurethane biomaterials.  The Company's expertise includes the development, co-development and supply of new proprietary materials, products and components to customers in the medical, industrial and consumer industry markets.

For more information please visit or call 888.308.3620.

About Cellon S.A.

CELLON is a rapidly growing company, established in 1987 to provide products and services to the vaccine production and bioprocessing industries. Areas of expertise include mammalian cell culture processes and the storage & transport of sterile liquids. Our success to-date has been built upon an understanding of the requirements of this demanding business sector - which has led to the formation of many collaborative relationships with our customers. Such partnerships have enabled us to develop a range of products to meet specific industry needs - in unique, often revolutionary, ways.

For more information please visit

SOURCE Biomerix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biomerix Granted US Patent for Its Proprietary Biomaterial Platform Technology
2. Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures
3. Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children
4. Geminus Corporation Named Recipient of Second Annual Netsmart Technologies Customer Innovation Award
5. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
6. DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
7. Techne Corporation Declares Dividend
8. Techne Corporation Announces Acquisition
9. SynapDx Corporation Licenses Autism Diagnostic Discoveries From Childrens Hospital Boston
10. Vestaron Corporation Announces New Leadership
11. Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by ... known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , ... have embraced this type of racing and several new model aviation pilots have joined ...
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
(Date:11/12/2015)... Nov. 11, 2015   Growing need for ... tools has been paving the way for use ... of discrete analytes in clinical, agricultural, environmental, food ... predominantly used in medical applications, however, their adoption ... due to continuous emphasis on improving product quality ...
Breaking Biology News(10 mins):